TheEdgeResearch
Home / Stocks / CBDNF

CBD Global Sciences Inc. (CBDNF)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.04 ▼ -2.67%
Market Cap
$2.1M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.43
52-Wk Range
0.016-0.121
CEO
Brad Wyatt
Country
US
Currency
USD

CBD Global Sciences Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Lakewood, CO, US. The stock last traded at $0.04, down 2.67% on the session, giving a market capitalisation of $2.1M. On trailing twelve-month figures it carries a trailing P/E of -0.28, a net margin of -3146.3%. Its beta of 0.43 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.28
Price / Sales
12.41
Price / Book
-0.88
EV / EBITDA
-1.08
Gross margin
24.6%
Operating margin
-1641.2%
Net margin
-3146.3%
Return on equity
—
Debt / equity
-1.41
Current ratio
0.16
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
—
IPO date
2021-01-08
Headquarters
Lakewood, CO, US
About CBD Global Sciences Inc.

CBD Global Sciences Inc. operates within the cannabidiol (CBD) sector, handling the cultivation, processing, and manufacturing of CBD products. Its offerings include biomass, various CBD oils, and other CBD-based items, which are marketed under the Aethics, CannaOil, and Strasburg Pharms brands. Founded in 2018, the company's main offices are located in Lakewood, Colorado.

Comparable companies

CBD Global Sciences Inc. is most often compared with the following Healthcare names:

ACNNFCANBCIMVFCPYTEEVVFETRGFKALOPARNFRCMWSILFF
More research on CBDNF
CBDNF technical analysis CBDNF TheEdge Score Compare against peers
Open full interactive analysis & DCF →